ASCO Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the American Society of Clinical Oncology.

Document Overview

Document Title: Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer

Authoring Society: American Society of Clinical Oncology

Document Publication Date: Jan 27, 2020

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: ascopubs.org/doi/full/10.1200/JCO.19.02960

Source Citation: DOI: 10.1200/JCO.19.02960 Journal of Clinical Oncology 38, no. 11 (April 10, 2020) 1222-1245.

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Document Objectives: The purpose of this clinical practice guideline is to provide clinicians (including but not limited to medical oncologists, radiation oncologists, gynecologic oncologists, and gynecologists), other health care practitioners, nurses, social workers, patients, and caregivers with recommendations regarding the role of genomic testing in epithelial ovarian cancer based on the best available evidence.

Scope: Assessment and Screening, Counseling

Keywords: BRCA, Epithelial Ovarian Cancer, Germline Testing, Somatic Tumor Testing

Target Patient Population: Women diagnosed with ovarian cancer and their families.

Target Provider Population: Medical, radiation, and surgical oncologists; gynecologic oncologists; gynecologists; geneticists; genetic counsellors

Inclusion Criteria: Female, Adult, Older Adult

Health Care Settings: Ambulatory, Outpatient, Radiology Services

Intended Users: Genetics, Nurse, Nurse Practitioner, Physician, Physician Assistant, Radiology Technologist

Recommendation Development Processes & Methodology

PICO Questions

In which individuals should risk evaluation, counseling, and genomic testing for germline and somatic tumor alterations be performed?
Which genomic alterations have demonstrated clinical utility to direct therapy for women with ovarian cancer?
What are the most appropriate sequencing and timing of testing?

Supplemental Methodology Resource: Data Supplement

Number of Source Documents: 19

Literature Search Start Date: Monday, January 1, 2007

Literature Search End Date: Tuesday, December 31, 2019

Includes peer/external review process?: Yes

Includes public comment process?: Yes

Methodologist involvement?: Yes

Patient involvement?: Yes

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: Yes

Identifies study selection process?: Yes

Identifies study selection criteria?: Yes

Identifies methods used to evaluate and analyze the evidence?: Yes

Identifies key questions addressed by the systematic review?: Yes

Identifies search strategy?: Yes